Literature DB >> 7094985

Diazepam plasma binding in the perinatal period: influence of nonesterified fatty acids.

M J Ridd, K F Brown, R G Moore, W G McBride, R L Nation.   

Abstract

The plasma binding of diazepam was determined serially in 24 women undergoing either elective induction of labour (vaginal or emergency caesarean delivery) or elective caesarean section at term and in 5 nonpregnant women requiring abdominal surgery. In the majority of pregnant patients, a marked increase in diazepam percentage free was observed during labour or prior to caesarean section, reaching a maximum, 1.6 to 3.2 fold increase at delivery or within 4 h postpartum; by the fifth day postpartum, diazepam percentage free was lower than on admission to hospital. In contrast, little change in diazepam percentage free was observed during the perisurgical period in nonpregnant patients. In parturient and surgical patients, the time courses of diazepam percentage free and plasma nonesterified fatty acid (NEFA) concentration were parallel. Bivariate regression analyses of pooled data demonstrated a strong correlation (r = 0.642, p = less than 0.010 between diazepam percentage free and corresponding NEFA concentration and a weaker correlation between diazepam percentage free and both albumin (r = 0.319, p less than 0.02) or total protein (r = 0.438, p less than 0.01). From multiple linear regression it was demonstrated that 54% of the variability in diazepam percentage free could be attributed to plasma NEFA and albumin concentrations. NEFA displacement of plasma bound diazepam was substantiated using crystalline human serum albumin. An approximate 65% increase in plasma alpha 1 acid glycoprotein levels was observed posttrauma in both parturient and surgical patients but was unrelated to diazepam binding events. A relationship between diazepam plasma binding changes and concurrently altered disposition of diazepam during parturition is postulated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094985     DOI: 10.1007/BF00542461

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Benzodiazepines: specific competitors for the binding of L-tryptophan to human serum albumin.

Authors:  W E Müller; U Wollert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

3.  Effect of synthetic oxytocin on plasma nonesterified fatty acids, triglycerides, and blood glucose.

Authors:  R L BURT; N H LEAKE; W N DANNENBURG
Journal:  Obstet Gynecol       Date:  1963-06       Impact factor: 7.661

4.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

5.  An improved method for the addition of long-chain free fatty acid to protein solutions.

Authors:  A A Spector; J C Hoak
Journal:  Anal Biochem       Date:  1969-11       Impact factor: 3.365

6.  Circular dichroism studies on the inhibiting effect of oleic acid on the binding of diazepam to human serum albumin.

Authors:  T Sjödin
Journal:  Biochem Pharmacol       Date:  1977-11-15       Impact factor: 5.858

7.  Differentiated effects of liver cirrhosis on the albumin binding sites for diazepam, salicylic acid and warfarin.

Authors:  A Kober; A Jenner; I Sjöholm
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

8.  Levels of free fatty acids and arachidonic acid in pregnancy and labor.

Authors:  P L Ogburn; S B Johnson; P P Williams; R T Holman
Journal:  J Lab Clin Med       Date:  1980-06

9.  The disposition kinetics of diazepam in pregnant women at parturition.

Authors:  R G Moore; W G McBride
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

10.  Effects of fatty acids on two specific drug binding sites on human serum albumin.

Authors:  D J Birkett; S P Myers; G Sudlow
Journal:  Mol Pharmacol       Date:  1977-11       Impact factor: 4.436

View more
  9 in total

Review 1.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

3.  Plasma binding of thiopentone in late pregnancy.

Authors:  D J Morgan; C T Toh; G L Blackman; J D Paull
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

4.  A short review of perinatal pharmacology.

Authors:  T Rosen; M S Schimmel
Journal:  Bull N Y Acad Med       Date:  1983-09

5.  Differential transplacental binding of valproic acid: influence of free fatty acids.

Authors:  F Albani; R Riva; M Contin; A Baruzzi; M Altomare; G P Merlini; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

6.  Differential transplacental binding of diazepam: causes and implications.

Authors:  M J Ridd; K F Brown; R L Nation; C B Collier
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Effect of caffeine on ceftriaxone disposition and plasma protein binding in the rat.

Authors:  K I Kwon; D W Bourne
Journal:  J Pharmacokinet Biopharm       Date:  1986-08

8.  Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels.

Authors:  H Nau; W Luck; W Kuhnz
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

9.  Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.

Authors:  I H Benedek; R A Blouin; P J McNamara
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.